Early Mental Response - The EMRE Study

Summary

Primary question: Does transgender men's experience of gender incongruence improve within 6 weeks of hormonal treatment compared to placebo? Long before any bodily changes occur. Secondary question: Does transgender men´s experience of self-esteem, quality of life, sexual desire, aggression, depression/anxiety, impulsiveness, and emotional reactivity improve during 6 weeks of cross-sex hormone therapy compared to placebo? Gender dysphoria is a condition characterized by a perceived incongruence between the body and identity. For several decades this condition has been treated with cross-sex hormone therapy and surgery, among others, in order to change the body to be more congruent with the perceived gender identity. Patient satisfaction with this treatment is very high where an overwhelming majority of patients live the rest of their lives according to their perceived gender. A clinical observation, however, is that most patients experience that the congruence between the perceived gender and the assigned one improves very quickly on hormonal treatment. Long before any changes to the body have taken place. This may be partly due to relief from having finally started treatment (i.e. a psychological/social explanation) but an alternative (and much more likely) explanation is that the hormonal treatment directly affects the brain. Since the cause of gender dysphoria is unknown today, this study is therefore a step in trying to clarify the mechanism. In addition, it is of value to be able to demonstrate the benefits of hormonal treatment in these patients. Finally, there is a basic research motive for this study. The effect of sex hormones on the brain is very well known from a clinical perspective but all the more unknown from a research perspective. This study will contribute knowledge in this area.

Timeline

Start

2023-03-07

Primary completion

2025-12-30

Completion

2026-12-30

Publications

• Background Mahfouda S, Moore JK, Siafarikas A, Hewitt T, Ganti U, Lin A, Zepf FD. Gender-affirming hormones and surgery in transgender children and adolescents. Lancet Diabetes Endocrinol. 2019 Jun;7(6):484-498. doi: 10.1016/S2213-8587(18)30305-X. Epub 2018 Dec 6.
• Background de Vries AL, McGuire JK, Steensma TD, Wagenaar EC, Doreleijers TA, Cohen-Kettenis PT. Young adult psychological outcome after puberty suppression and gender reassignment. Pediatrics. 2014 Oct;134(4):696-704. doi: 10.1542/peds.2013-2958. Epub 2014 Sep 8.
• Background Frisen L, Soder O, Rydelius PA. [Dramatic increase of gender dysphoria in youth]. Lakartidningen. 2017 Feb 22;114:EFMY. Swedish.
• Background American Psychiatric association. Diagnostic and statistical manual of mental disorders, 5th edition (DSM-5). Arlington VA; 2013.
• Background World Health Organization. International statistical classification of diseases and related health problems, 10th revision (ICD-10). Geneva; 1992.
• Background World Professional Association for Transgender Health (WPATH). Standards of Care for the Health of Transsexual, Transgender, and Gender Nonconforming People (7th version). 2009.
• Background Socialstyrelsen. God vård av vuxna med könsdysfori. 2015.
• Background Hembree WC, Cohen-Kettenis P, Delemarre-van de Waal HA, Gooren LJ, Meyer WJ 3rd, Spack NP, Tangpricha V, Montori VM; Endocrine Society. Endocrine treatment of transsexual persons: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2009 Sep;94(9):3132-54. doi: 10.1210/jc.2009-0345. Epub 2009 Jun 9.
• Background Gijs L, Brewaeys A. Surgical Treatment of Gender Dysphoria in Adults and Adolescents: Recent Developments, Effectiveness, and Challenges. Annu Rev Sex Res. Taylor & Francis; 2007 Mar 1;18(1):178-224.
• Background Smith YL, Van Goozen SH, Kuiper AJ, Cohen-Kettenis PT. Sex reassignment: outcomes and predictors of treatment for adolescent and adult transsexuals. Psychol Med. 2005 Jan;35(1):89-99. doi: 10.1017/s0033291704002776.
• Background Davy Z. The DSM-5 and the Politics of Diagnosing Transpeople. Arch Sex Behav. 2015 Jul;44(5):1165-76. doi: 10.1007/s10508-015-0573-6.
• Background Zeluf G, Dhejne C, Orre C, Nilunger Mannheimer L, Deogan C, Hoijer J, Ekeus Thorson A. Health, disability and quality of life among trans people in Sweden-a web-based survey. BMC Public Health. 2016 Aug 30;16(1):903. doi: 10.1186/s12889-016-3560-5.
• Background Collin L, Reisner SL, Tangpricha V, Goodman M. Prevalence of Transgender Depends on the "Case" Definition: A Systematic Review. J Sex Med. 2016 Apr;13(4):613-26. doi: 10.1016/j.jsxm.2016.02.001. Epub 2016 Mar 25.
• Background Bockting W, Knudson G, Goldberg JM, Goldberg J, Lindenberg D, Hunt R, et al. Counselling and Mental Health Care of Transgender Adults and Loved Ones. 2006.
• Background Newfield E, Hart S, Dibble S, Kohler L. Female-to-male transgender quality of life. Qual Life Res. 2006 Nov;15(9):1447-57. doi: 10.1007/s11136-006-0002-3. Epub 2006 Jun 7.
• Background Pfäfflin F, Junge A. Thirty years of international follow-up studies after sex reassignment surgery: a comprehensive review 1961-1991. 1998.
• Background Läkemedelsindustriföreningen. Androcur [Internet]. Fass. 2018. Available from: https://www.fass.se/LIF/product?userType=0&nplId=19780414000015
• Background McEwen BS, Alves SE. Estrogen actions in the central nervous system. Endocr Rev. 1999 Jun;20(3):279-307. doi: 10.1210/edrv.20.3.0365. No abstract available.
• Background Kuhl H. Pharmacology of estrogens and progestogens: influence of different routes of administration. Climacteric. 2005 Aug;8 Suppl 1:3-63. doi: 10.1080/13697130500148875.
• Background Douma SL, Husband C, O'Donnell ME, Barwin BN, Woodend AK. Estrogen-related mood disorders: reproductive life cycle factors. ANS Adv Nurs Sci. 2005 Oct-Dec;28(4):364-75. doi: 10.1097/00012272-200510000-00008.
• Background Champe PC, Harvey RA, Ferrier DR. Biochemistry. 4th ed. Baltimore; 2008.
• Background Wang C, Liu Y, Cao JM. G protein-coupled receptors: extranuclear mediators for the non-genomic actions of steroids. Int J Mol Sci. 2014 Sep 1;15(9):15412-25. doi: 10.3390/ijms150915412.
• Background Banks WA. Brain meets body: the blood-brain barrier as an endocrine interface. Endocrinology. 2012 Sep;153(9):4111-9. doi: 10.1210/en.2012-1435. Epub 2012 Jul 9.
• Background Cyr M, Calon F, Morissette M, Grandbois M, Di Paolo T, Callier S. Drugs with estrogen-like potency and brain activity: potential therapeutic application for the CNS. Curr Pharm Des. 2000 Aug;6(12):1287-312. doi: 10.2174/1381612003399725.
• Background Perfalk E, Cunha-Bang SD, Holst KK, Keller S, Svarer C, Knudsen GM, Frokjaer VG. Testosterone levels in healthy men correlate negatively with serotonin 4 receptor binding. Psychoneuroendocrinology. 2017 Jul;81:22-28. doi: 10.1016/j.psyneuen.2017.03.018. Epub 2017 Mar 22.
• Background Nieschlag E, Behre HM. Testosterone: action, deficiency, substitution. 4th ed. Cambridge: Cambridge University Press; 2012.
• Background Zarrouf FA, Artz S, Griffith J, Sirbu C, Kommor M. Testosterone and depression: systematic review and meta-analysis. J Psychiatr Pract. 2009 Jul;15(4):289-305. doi: 10.1097/01.pra.0000358315.88931.fc.
• Background Rohr UD. The impact of testosterone imbalance on depression and women's health. Maturitas. 2002 Apr 15;41 Suppl 1:S25-46. doi: 10.1016/s0378-5122(02)00013-0.
• Background Defreyne J, Elaut E, Kreukels B, Fisher AD, Castellini G, Staphorsius A, Den Heijer M, Heylens G, T'Sjoen G. Sexual Desire Changes in Transgender Individuals Upon Initiation of Hormone Treatment: Results From the Longitudinal European Network for the Investigation of Gender Incongruence. J Sex Med. 2020 Apr;17(4):812-825. doi: 10.1016/j.jsxm.2019.12.020. Epub 2020 Jan 31.
• Background Pope HG Jr, Cohane GH, Kanayama G, Siegel AJ, Hudson JI. Testosterone gel supplementation for men with refractory depression: a randomized, placebo-controlled trial. Am J Psychiatry. 2003 Jan;160(1):105-11. doi: 10.1176/appi.ajp.160.1.105.

Drugs

Indications

No indication recorded.